Celltech

Celltech was a British biotechnology company established in 1980 to address a perceived failure by the United Kingdom to commercialise discoveries emerging from publicly funded science. The company was created against the background of advances in biotechnology, particularly monoclonal-antibody technology, and was intended to provide a bridge between university and government research and private-sector drug development. Its formation involved the National Enterprise Board, the National Research Development Corporation and the Medical Research Council. The founding model gave Celltech broad access to biotechnology discoveries made in UK research institutions and universities, while ensuring that private investors held a majority stake. The company became one of the United Kingdom's earliest major biotechnology businesses. Its founding chief executive, Gerard Fairtlough, developed the original plan and led the organisation during its formative decade. Celltech's importance extended beyond its own products: it became an influential example of how British scientific research could be organised, financed and transferred into commercial biotechnology. The company also pioneered work in recombinant-protein production, including cloning the glutamine synthetase gene in Chinese hamster ovary cells. The resulting expression system became a widely used tool for producing recombinant eukaryotic proteins. Celltech's business combined research and development with ownership, licensing and commercialisation of pharmaceutical products. Its activities covered therapies and products for serious diseases as well as established medicines, including treatments for cough, edema, attention-deficit hyperactivity disorder, narcolepsy and allergic conditions. It also developed antibody-drug programmes through collaboration with Wyeth, including the antibody-drug conjugates later known as inotuzumab ozogamicin and gemtuzumab ozogamicin. During the late 1990s and early 2000s, Celltech pursued consolidation and international expansion. In 1999 it merged with Chiroscience plc and was temporarily known as Celltech Chiroscience before acquiring Medeva. It bought the United States biosciences company Cistron in 2000, expanded into Germany through the acquisition of Thiemann in 2001, and acquired Oxford Glycosciences in July 2003 for £102 million. These transactions broadened the group from a UK biotechnology pioneer into a larger international biopharmaceutical company with research, development and commercial capabilities. Celltech was listed on the London Stock Exchange and became a constituent of the FTSE 100 Index. Its independent existence ended when Belgian pharmaceutical company UCB acquired it in 2004. Following the transaction, Celltech's operations and assets were integrated into UCB and the standalone Celltech identity was progressively discontinued. The company's lasting significance lies in its role in the formation of the British biotechnology industry, its contribution to technology transfer and recombinant-protein production, and the drug-development programmes that continued under successor ownership.

Celltech was formed in 1980 in response to concern that Britain was not converting its scientific achievements into successful commercial businesses. The emergence of modern biotechnology, together with the development of monoclonal-antibody methods in Cambridge, highlighted the commercial potential of biological research and the risk that British discoveries would be exploited elsewhere. Celltech was designed to create an institutional route from publicly funded research to industrial products. Its creation involved the National Enterprise Board, the National Research Development Corporation and the Medical Research Council. The original concept gave the company exclusive rights to biotechnology discoveries produced across UK research institutions and universities. Although the initiative was conceived under a Labour government, Celltech was established under a Conservative government. Industry minister Sir Keith Joseph supported a structure in which the private sector held the majority of the company, reflecting the government's preference for commercial discipline rather than direct state control. Gerard Fairtlough, who had worked at the National Enterprise Board, developed the plan and became Celltech's founding chief executive. During roughly the first decade of the company's life, he helped build an organisation intended both to conduct high-level biological research and to demonstrate that British science could support a profitable, investor-backed biotechnology enterprise. Celltech became an important institutional example for the later development of the UK's biotechnology sector and contributed to changes in the way research institutions approached technology transfer. The company's technical work included the cloning of the glutamine synthetase gene in Chinese hamster ovary cells. This work produced a biotechnology tool for expressing recombinant proteins in eukaryotic cells and became widely used in the manufacture and study of biological products. Celltech also developed and commercialised medicines across several therapeutic areas. Products associated with the company included Tussionex for cough, Zaroxolyn for difficult-to-treat edema, methylphenidate and Dexedrine for attention-deficit hyperactivity disorder or narcolepsy, and Semprex-D for allergy and nasal-congestion symptoms. Celltech increasingly used acquisitions and combinations to expand its capabilities. In 1999 it merged with Chiroscience plc, creating a larger UK bioscience group that was briefly called Celltech Chiroscience. It then acquired Medeva. In 2000 Celltech bought Cistron in the United States, followed by the acquisition of German biosciences company Thiemann in 2001. In July 2003 it acquired Oxford Glycosciences for £102 million. These transactions expanded its geographic reach and added research, development and commercial assets. Celltech's antibody research also produced important collaborations. In partnership with Wyeth, it worked on antibody-drug conjugates including gemtuzumab ozogamicin and inotuzumab ozogamicin. The company therefore combined established pharmaceutical products with newer biologic and biotechnology programmes. It was listed on the London Stock Exchange and became a FTSE 100 constituent, giving it a prominent position among British public companies. UCB acquired Celltech in 2004. The acquisition brought Celltech's research programmes, products and technology platforms into the Belgian pharmaceutical group. Celltech subsequently ceased to operate as an independent corporate brand. Its historical contribution is associated with building one of the UK's earliest biotechnology companies, demonstrating a model for commercialising publicly funded biological research, advancing recombinant-protein expression technology and originating programmes that continued under successor organisations.

1. 2004Acquisition by UCB

   UCB acquires Celltech, ending its independent corporate existence.

   Source
2. 2003Acquisition of Oxford Glycosciences

   Celltech acquires Oxford Glycosciences in July for £102 million.

   Source
3. 2001Acquisition of Thiemann

   Celltech buys German biosciences company Thiemann and expands its European operations.

   Source
4. 2000Acquisition of Cistron

   Celltech acquires the US biosciences business Cistron.

   Source
5. 1999Merger with Chiroscience

   Celltech merges with Chiroscience plc during a period of consolidation in the UK biosciences market.

   Source
6. 1980Celltech is established

   Celltech is created to commercialise biotechnology discoveries from UK research institutions and universities.

   Source
7. 1980Gerard Fairtlough becomes founding chief executive

   Gerard Fairtlough, who developed the company's plan while working at the National Enterprise Board, becomes its first chief executive.

   Source

Early British biotechnology pioneer focused on transferring publicly funded biological research into commercial therapeutics and technology platforms.

• Gemtuzumab ozogamicinAntibody-drug conjugate

  An antibody-drug conjugate programme developed through Celltech's collaboration with Wyeth. The project combined antibody targeting with a cytotoxic payload and represented Celltech's move toward advanced biologic therapeutics for serious disease.

• Inotuzumab ozogamicinAntibody-drug conjugate

  An antibody-drug conjugate originating from work conducted through Celltech's collaboration with Wyeth. It exemplified the company's focus on engineered antibody-based medicines and drug-development platforms.

• TussionexCough medicine

  A cough-treatment product included among the medicines associated with Celltech's commercial operations.

• ZaroxolynDiuretic

  A medicine used in the treatment of resistant edema and included in Celltech's established pharmaceutical portfolio.

• DexedrineCentral-nervous-system medicine

  A 5 mg amphetamine tablet associated with Celltech's portfolio and used for attention-deficit hyperactivity disorder and narcolepsy.

• Semprex-DAntihistamine and decongestant

  A combination antihistamine and decongestant product associated with Celltech's commercial medicines business.

• Glutamine synthetase expression systemBiotechnology platform

  Celltech's cloning of the glutamine synthetase gene in Chinese hamster ovary cells produced a tool for recombinant-protein expression. The platform became broadly useful in biotechnology for expressing recombinant eukaryotic proteins.

• 2004Accept acquisition by UCBM&A

  Celltech had become a substantial international biopharmaceutical group through organic development, partnerships and acquisitions.

  What changed. Belgian pharmaceutical company UCB acquired Celltech.

  Aftermath. Celltech ceased to exist as an independent company and its activities were integrated into UCB.

  Source
• 2003Acquire Oxford GlycosciencesM&A

  Celltech used acquisitions to add scientific capabilities and strengthen its biopharmaceutical pipeline.

  What changed. Celltech acquired Oxford Glycosciences in July 2003 for £102 million.

  Aftermath. The transaction added Oxford Glycosciences' biotechnology assets to Celltech before the later UCB acquisition.

  Acquisition value. £102 million (July 2003)

  Source
• 2001Acquire ThiemannM&A

  Celltech continued its international expansion after its earlier UK and US transactions.

  What changed. The company acquired German biosciences business Thiemann.

  Aftermath. Celltech established a stronger operating presence in Germany and continental Europe.

  Source
• 2000Acquire CistronM&A

  Celltech aimed to build an international biotechnology platform and strengthen its presence in the United States.

  What changed. Celltech acquired US biosciences company Cistron.

  Aftermath. The acquisition expanded Celltech's research and commercial footprint beyond the UK.

  Source
• 1999Combine with ChiroscienceM&A

  Celltech sought greater scale and broader capabilities during consolidation in the UK biotechnology and biosciences market.

  What changed. The company merged with Chiroscience plc and was temporarily known as Celltech Chiroscience.

  Aftermath. The combination formed the basis for further portfolio expansion, including the acquisition of Medeva.

  Source

• 2004UCB acquires Celltech

  Belgian pharmaceutical company UCB acquired Celltech. The transaction ended Celltech's independent corporate existence and led to the integration of its activities into UCB.

  M&A
  Source
• 2003Celltech acquires Oxford Glycosciences

  Celltech acquired Oxford Glycosciences in July 2003 for £102 million, adding capabilities and assets in biotechnology and glycoprotein-related research.

  M&A
  Source
• 2001Celltech expands into Germany through Thiemann acquisition

  The acquisition of German biosciences company Thiemann extended Celltech's European presence and supported its internationalisation strategy.

  M&A
  Source
• 2000Celltech acquires Cistron

  Celltech expanded its United States biotechnology activities by acquiring Cistron, broadening its research and commercial footprint outside the United Kingdom.

  M&A
  Source
• 1999Celltech merges with Chiroscience and leads UK bioscience consolidation

  Celltech merged with Chiroscience plc as part of a consolidation strategy in the United Kingdom's biotechnology sector. The combined business was temporarily identified as Celltech Chiroscience before subsequent corporate changes.

  M&A
  Source

1. Celltech